Innovative Idea Generating Centre
Gurpreet Singh Vice President, Managing Director Integrated Safety IQVIA
Gurpreet Singh is the Vice President and Managing Director of Integrated Safety at IQVIA, based in the UK. With 19 years of experience in the pharmaceutical industry, 16+ of which have been focused on global drug development, Gurpreet has worked with renowned global companies such as Cognizant, Tata Consultancy, Novartis, and Parexel. At Novartis, he served as the Global Head of Pharmacovigilance (PV) Operations, overseeing all global PV activities. At Parexel, he was the Senior Director of PV Operations, responsible for managing PV projects for leading pharmaceutical and biotech companies. Gurpreet is certified in Six Sigma and Project Management and has a strong passion for Digital Transformation and Organizational Culture. Throughout his career, he has successfully led numerous projects within the pharmaceutical industry. Additionally, he is an avid runner and a frequent speaker at various pharmaceutical conferences.
REVOLUTIONIZING PHARMACOVIGILANCE AND RISK MANAGEMENT CONFERENCE SPEAKERS
Lizanne Pistorius Head of Patient Safety & Pharmacovigilance Boehringer Ingelheim
Lizanne Pistorius is an accomplished executive with extensive experience in pharmacovigilance, patient safety, and healthcare leadership. As the Head of Patient Safety & Pharmacovigilance at Boehringer Ingelheim, Lizanne leads a dedicated team responsible for ensuring the safety and well-being of patients worldwide by overseeing comprehensive risk management strategies, monitoring drug safety, and ensuring regulatory compliance.
With a passion for advancing healthcare and improving patient outcomes, Lizanne has built a career that bridges the scientific, regulatory, and ethical aspects of drug safety. Her leadership and strategic vision have been instrumental in driving innovation within Boehringer Ingelheim's safety and pharmacovigilance operations. She is deeply committed to fostering a culture of patient-centered care and ensuring that the company's products meet the highest safety standards.
Sanket Mahajan Safety Scientist PV Shionogi Europe
Sanket Mahajan is a born leader and a highly driven pharmacovigilance professional with a passion for patient safety and drug innovation. Currently serving as a Safety Scientist at Shionogi Europe, Sanket brings a wealth of expertise in end-to-end drug safety management, encompassing the management of product safety profiles, safety information in clinical trials, and signal management. He excels in authoring and maintaining comprehensive risk management plans at both the European and global levels.
Trilingual and results-oriented, Sanket is deeply committed to driving positive change in healthcare by prioritizing patient well-being. His approach focuses on ensuring the highest standards of drug safety while fostering innovation that improves patient outcomes. With a clear mission to contribute to the development of innovative medicinal products that save lives, Sanket’s work is guided by his strong belief that patient safety must always be at the center of all decision-making.
Holding a Master’s degree in Pharmaceutical Science with Management from Kingston University, London, Sanket is a natural communicator, eager to share knowledge and continuously expand his expertise.
Geeta N. Shanbhag Vice President Pharmacovigilance & Medico-regulatory Affairs Ipca Laboratories Ltd.
Geeta N. Shanbhag is an accomplished pharmaceutical industry leader with nearly three decades of diverse experience spanning across regulatory affairs, clinical research, medico-marketing, bioequivalence studies, pre-clinical studies, and pharmacovigilance. Currently serving as the Vice President of Pharmacovigilance & Medico-regulatory Affairs at Ipca Laboratories Ltd., Geeta has played a pivotal role in advancing the company’s global pharmacovigilance operations.
A management postgraduate with a strong pharmaceutical background, Geeta has been at the forefront of building and overseeing Ipca's in-house pharmacovigilance department, which manages end-to-end pharmacovigilance on a global scale. Her leadership and expertise have been instrumental in the company’s success, including the clearance of its first US FDA pharmacovigilance inspection in 2017.
Her deep knowledge of the pharmaceutical industry, combined with her passion for patient safety, has made her a key figure in advancing pharmacovigilance practices globally.
Michael Von Forstner Head of Global Safety Science Sobi – Swedish Orphan Biovitrum AB (publ)
Michael Von Forstner is an experienced and highly regarded executive with 25 years of expertise in pharmacovigilance, pharmacoepidemiology, and benefit-risk management within the pharmaceutical and biotech industries. As the Head of Global Safety Science at Sobi – Swedish Orphan Biovitrum AB (publ), Michael leads global efforts to ensure patient safety, with a focus on developing and managing robust pharmacovigilance and risk management systems.
With a comprehensive background that spans both academic and industrial R&D settings, Michael brings a deep understanding of patient safety across all stages of drug development and commercialization. His energetic and goal-oriented approach, combined with his creative problem-solving capabilities, has made him a driving force for innovation and change in the field of pharmacovigilance.
Michael’s expertise and strong leadership are pivotal in guiding Sobi’s safety science initiatives, ensuring that the company’s innovative therapies are safe, effective, and aligned with the highest industry standards.
David Gillen Chief Medical Officer Norgine
David is the Chief Medical Officer at Norgine, a role he has held since May 2022. He qualified in Medicine, Physiology, and Clinical Pharmacology at St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992, and his passion for Pharmaceutical Medicine led him to pursue postgraduate training in Cardiology and General Medicine. David began his industry career in 1999 at Pfizer Global Research and Development in Sandwich.
After his tenure at Pfizer, David went on to become Head of International Medical Affairs at Gilead Sciences. In 2011, he joined Celgene Ltd. as Head of Drug Safety and Risk Management for the EMEA/APAC regions, and also served as the Qualified Person for Pharmacovigilance (QPPV) for Celgene’s Pharmacovigilance System in Europe. In 2016, David took on the role of Vice President of International Medical Affairs at Vertex, and by 2019, he assumed additional oversight of the entire International Global Development and Medical Affairs function.
Giovanni Furlan Senior pharmacovigilance professional
With 20 years of experience in drug safety and a strong foundation in Chemistry and Pharmaceutical Technology, Giovanni Furlan is a qualified pharmacist and a seasoned expert in pharmacovigilance. His career began with case processing at a major pharmaceutical company, evolving into leadership roles where he has established, developed, and integrated pharmacovigilance departments and systems.
As a Qualified Person Responsible for Pharmacovigilance (EU QPPV) and Local Responsible Person for Pharmacovigilance, Giovanni has successfully led global operational and benefit-risk teams. He has worked across local, European, and global levels in both medium and large pharmaceutical companies as well as in a CRO environment.
Giovanni possesses a unique blend of operational expertise and scientific acumen, covering all aspects of pharmacovigilance systems, aggregate report preparation, signal detection and evaluation, benefit-risk assessment, and regulatory interactions.
Valentina Mancini Senior Director, Pharmacovigilance & QPPV Shionogi Europe
Valentina is a highly experienced pharmacist, currently serving as the Senior Director of Pharmacovigilance and QPPV at Shionogi, where she is responsible for the implementation of PV systems across the EEA and the UK, as well as overseeing Operations and Compliance. With an extensive career at Pfizer, Takeda, and Baxter, she has progressively taken on increasing responsibilities within Pharmacovigilance.
Her expertise also spans Clinical QA and Medical Information. Valentina is an active member of Transcelerate and lectures in academic post-graduate courses. She values building strong business networks and maintaining professional relationships, regularly speaking at congresses and seminars. Additionally, she contributes to working groups within scientific societies and pharmaceutical industry associations.
©Copyright. All rights reserved.
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.